New Delhi: The World Health Organisation on Friday approved emergency use listing of Covid vaccine Covovax, produced by the Serum Institute of India under licence from Novavax and part of the Covax facility portfolio. “This is yet another milestone in our fight against Covid-19. Covovax is now WHO approved for emergency use, showing excellent safety […]
Mumbai: The Pune-based Serum Institute of India (SII) will launch Covavax — its vaccine for children aged above 3 years — in the next six months, SII CEO Adar Poonawalla said here on Tuesday. Covavax is currently under trial and has shown excellent results down to the age of 3 years, Poonawalla said while addressing […]
"Excited to witness the first batch of Covovax (developed by @Novavax) being manufactured this week at our facility in Pune," he shared in a tweet on Friday.
The Phase 2b randomised, observer-blinded, placebo-controlled trial conducted in South Africa evaluated efficacy, safety and immunogenicity in healthy adults, and in a small cohort of medically stable adults
NVX-CoV2373 has the potential to play an important role in solving this global public health crisis. We look forward to continuing to work with our partners, collaborators, investigators and regulators